الملخص
Objective@#To compare the clinical efficacy and safety of concurrent chemoradiotherapy and sequential chemoradiotherapy for bone metastasis of non-small cell lung cancer(NSCLC).@*Methods@#This was a retrospective cohort study, in which 120 patients with bone metastases from NSCLC admitted to our hospital from June 2013 to June 2018 were enrolled.Of these patients, 60 received sequential chemotheradiotherapy and 60 patients received concurrent chemoradiotherapy.Bone pain was measured before treatment, at 1-month, 2-months into treatment, and 1-month after treatment.Short-term efficacy and adverse reactions were compared between the two groups.@*Results@#There were no significant differences in pain relief rate at 1-month, 2-months into treatment and 1-month after treatment between the two groups(all P>0.05). Meanwhile, the objective response rate(50.0% vs.36.7%)and disease control rate(90.0% vs.83.3%)were also similar between the two groups(χ2=2.172, 1.154, P=0.141, 0.283). The incidences of toxic and side effects, including neutropenia(90.0% vs.60.0%), leukopenia(96.7% vs.63.3%)and nausea(50.0% vs.23.0%)were significantly higher in the concurrent chemoradiotherapy group than those in the sequential chemotherapy/radiotherapy group(all P<0.05). However, the rates of other toxic and side effects such as thrombocytopenia, vomiting, fatigue and alopecia were comparable between the two groups(all P>0.05).@*Conclusions@#Compared with sequential chemoradiotherapy, concurrent chemoradiotherapy has similar short-term efficacy in pain relief for bone metastasis of NSCLC, but the incidence of side effects is higher.
الملخص
Objective To compare the clinical efficacy and safety of concurrent chemoradiotherapy and sequential chemoradiotherapy for bone metastasis of non-small cell lung cancer (NSCLC).Methods This was a retrospective cohort study,in which 120 patients with bone metastases from NSCLC admitted to our hospital from June 2013 to June 2018 were enrolled.Of these patients,60 received sequential chemotheradiotherapy and 60 patients received concurrent chemoradiotherapy.Bone pain was measured before treatment,at 1-month,2-months into treatment,and 1-month after treatment.Short-term efficacy and adverse reactions were compared between the two groups.Results There were no significant differences in pain relief rate at 1-month,2-months into treatment and 1-month after treatment between the two groups (all P ＞0.05).Meanwhile,the objective response rate (50.0％ vs.36.7％) and disease control rate (90.0％ vs.83.3％) were also similar between the two groups(x2 =2.172,1.154,P =0.141,0.283).The incidences of toxic and side effects,including neutropenia(90.0 ％ vs.60.0 ％),leukopenia(96.7 ％ vs.63.3 ％) and nausea(50.0 ％ vs.23.0％)were significantly higher in the concurrent chemoradiotherapy group than those in the sequential chemotherapy/radiotherapy group(all P＜0.05).However,the rates of other toxic and side effects such as thrombocytopenia,vomiting,fatigue and alopecia were comparable between the two groups(all P ＞ 0.05).Conclusions Compared with sequential chemoradiotherapy,concurrent chemoradiotherapy has similar short-term efficacy in pain relief for bone metastasis of NSCLC,but the incidence of side effects is higher.
الملخص
Objective To investigate the protective effect of Addie on cardiac injury induced by radiotherapy and chemotherapy in patients with cervical cancer.Methods 74 cases of cervical cancer were collected from the oncology department of Zhousha Hospital, those were treated with surgery and radiotherapy and chemotherapy according to postoperative staging and classification of cases.The patients were randomly divided into the experimental group and the control group, with 37 cases in each group.Control group received leukogenic and antiemetic treatment,the experimental group were given Addie injection 100 mL intravenous drip on the basis of the control group, one times per day,10 days as one courses, and two groups were all received 6 courses of treatment.Atthe end of treatment, the condition of heart function, left ventricular ejection fraction, left ventricular end diastolic diameter, 6 minutes walk test, myocardial enzymes, troponin T, C reactive protein /Barhel quality of life score index, EORTC-QLQ score and the incidence of adverse reactions were detected and compared with two groups.Results After treatment, the cardiac function of the experimental group was significantly better than that of the control group (P<0.05).After treatment,LVEDD of two groups decreased (P<0.05), LVEF, 6 minutes walk test distance increased (P<0.05),and LVEDD of experimental group was lower than control group (P<0.05), LVEF, 6 minutes walk test distance higher (P<0.05).After treatment, creatine kinase and creatine kinase levels were increased in two groups (P<0.05).Compared with the control group, the level of creatine kinase and creatine kinase in experimental group were higher(P <0.05).After treatment,the levels of troponin T and C reactive protein in two groups were decreased ( P <0.05 ) .Compared with the control group, the levels of troponin T and C reactive protein in experimental group were lower (P<0.05).After treatment,the scores of Barhel index and EORTC-QLQ score of two groups were significantly higher than before treatment, and the quality of life of the experimental group was significantly higher than that of control group ( P <0.05 ) .There was no significant difference in the incidence of adverse reactions between two groups.Conclusion Addie has an obvious protective effect on cardiac injury induced by radiotherapy and chemotherapy in patients with cervical cancer, and can improve the quality of life of patients.
الملخص
Objective To investigate the protective effect of Shen Mai injection in the treatment of lung injury induced by radiotherapy in patients with advanced breast cancer. Methods 80 cases with lung injury induced by radiotherapy in patients with advanced breast cancer from our hospital from 2015.1 to 2016.5 were selected and randomly divided into 2 groups, 40 cases in control group were given routine treatment, 40 cases in the experimental group were treated based on the control group treated with Shenmai injection treatment, and 2 groups were treated for 4 weeks. The pulmonary function, T lymphocyte subsets, clinical symptoms, quality of life scores and clinical efficacy were observed before and after treatment in two groups. The results were analyzed by statistical software SPSS 19.0. Results Compared with before treatment, levels of FVC, FEV1 and TLC in 2 groups after treatment elevated, scores of respiratory symptoms, activities, and daily life effect decreased, levels of serum CD3+, CD4+, CD4+/CD8+elevated, levels of CD8+ decreased, and compared with the control group, levels of FVC, FEV1, TLC, CD3+, CD4+, CD4+/CD8+ in the experimental group were higher, scores of respiratory symptoms, activities, and daily life effect were lower, clinical effect rate was higher, the differences were statistically significant (P<0.05). Conclusion Shen Mai injection can effectively improve lung function and immunity, improve respiratory symptoms and improve the quality of life in patients with advanced breast cancer radiotherapy for lung injury, and has better clinical efficacy.